KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Regeneron Pharmaceuticals (REGN) Notes Payables (2020)

Regeneron Pharmaceuticals (REGN) has disclosed Notes Payables for 3 consecutive years, with $1.5 billion as the latest value for Q2 2020.

For Q2 2020, Notes Payables changed N/A year-over-year to $1.5 billion; the TTM value through Jun 2020 reached $1.5 billion, changed N/A, while the annual FY2015 figure was $1.6 million, 78.67% down from the prior year.
Notes Payables hit $1.5 billion in Q2 2020 for Regeneron Pharmaceuticals, up from $1.6 million in the prior quarter.
Across five years, Notes Payables topped out at $1.5 billion in Q2 2020 and bottomed at $1.5 billion in Q2 2020.